Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments

Camille Tessier, Richard Leblanc, Jean Roy, Sabrina Trudel, Julie Cote, Marc Lalancette, Jean-Samuel Boudreault, Emilie Lemieux-Blanchard, Rayan Kaedbey, Michel Pavic

Blood (2023) 142 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2023-173362

Published: 2023

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Richard LeBlanc, MDFRCPC, Imran Ahmad, MD M.Sc., Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD, Jean-Sébastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MDFRCPC, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2017) 130 (Supplement 1): 4556.

https://doi.org/10.1182/blood.V130.Suppl_1.4556.4556

Published: 2017

Journal Articles

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Claudie Lavoie-Gagnon, MD, Jonathan St-Gelais, MD, Jean-Philippe Adam, BPharm, MSc, BCPS, BCOP, Daniel Viens, MD FRCPC, Félixe Gagné, Pharm.D., MSc, Yann Décarie, MSc, Emilie Lemieux-Blanchard, BSc,MD

Blood (2017) 130 (Supplement 1): 1870.

https://doi.org/10.1182/blood.V130.Suppl_1.1870.1870

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Richard LeBlanc, MD, Imran Ahmad, MD, Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2016) 128 (22): 2306.

https://doi.org/10.1182/blood.V128.22.2306.2306

Published: 2016

Journal Articles

Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada

Nathalie Marcotte, B.Pharm, MSc, Marie-Claude Michel, Louise Deschenes, MD, Nathalie Letarte, BPharm, MSc, BCOP, Daniel Froment, MD, Emilie Lemieux-Blanchard, BSc,MD FRCPC, France Varin, Ghislain Bérard, Paul Farand, MD, Élaine Pelletier, Pierre Gaudreault, MD, Chantal Guévremont, Raghu Rajan, MD, Michael Sebag

Blood (2015) 126 (23): 5573.

https://doi.org/10.1182/blood.V126.23.5573.5573

Published: 2015

Journal Articles

Targeting Patient at High Risk of Thrombocytopenia and Neutropenia with Cybord, Vel-Dex and VMP: Time to Decrease the Number of Blood Tests ?

Jean-Philippe Adam, B. Pharm., M.Sc., BCPS, Emilie Lemieux-Blanchard, BSc,MD FRCPC, Bernard Lemieux, MD FRCP, Nathalie Letarte, BPharm, MSc, BCOP

Blood (2014) 124 (21): 1295.

https://doi.org/10.1182/blood.V124.21.1295.1295

Published: 2014

Journal Articles

First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital

Jean-Philippe Adam, B. Pharm., M.Sc., Emilie Lemieux-Blanchard, BSc, MD, FOnline-OnlyPC, Bernard Lemieux, MD, FOnline-OnlyP, Nathalie Letarte, BPharm, MSc, BCOP

Blood (2013) 122 (21): 5610.

https://doi.org/10.1182/blood.V122.21.5610.5610

Published: 2013

NARROW

Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada

Targeting Patient at High Risk of Thrombocytopenia and Neutropenia with Cybord, Vel-Dex and VMP: Time to Decrease the Number of Blood Tests ?

First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only